Kanglaite
ApprovedSmall molecule
Kanglaite is one of 103 small molecule programs targeting Cachexia. It is currently in Approved.
3
Indications
5
Total Trials
0
Active Trials
102
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
598 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Lynparza
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cachexia2 trials
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kanglaite. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details